VTAK · Catheter Precision, Inc.

Options vest 100% on 180 day anniversary of grant date.

Options vest 100% on 180 day anniversary of grant date.

Options vest 100% on 180 day anniversary of grant date.

Options vest 100% on 180 day anniversary of grant date.

Options vest 100% on 180 day anniversary of grant date.

Series J Exchange Agreement entered into with the Company to cancel accrued royalty amount and terminate royalty right in exchange for Series J Preferred Stock, as more fully described in the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 12, 2026 (the "Form 8-K").

The consideration and price paid for the Series J Preferred Stock is more fully described in the Form 8-K.

Series J Preferred Stock is not exercisable until stockholder approval is received, as more fully described in the Form 8-K.

Series J Preferred Stock has no expiration date.

Mr. Jenkins is the managing member of SeaCap Management LLC, the general partner of FatBoy Capital LP.

Series J Exchange Agreement entered into with the Company to cancel accrued royalty amount and terminate royalty right in exchange for Series J Preferred Stock, as more fully described in the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 12, 2026 (the "Form 8-K").

The consideration and price paid for the Series J Preferred Stock is more fully described in the Form 8-K.

Series J Preferred Stock is not exercisable until stockholder approval is received, as more fully described in the Form 8-K.

Series J Preferred Stock has no expiration date.

Initial Exercise Date is any time on or after the Stockholder Approval Date.

Termination Date equals the Five and One Half (5.5) Year Anniversary of the Initial Exercise Date

Mr. Jenkins is the managing member of SeaCap Management LLC, the general partner of FatBoy Capital LP

Initial Exercise Date is any time on or after the Stockholder Approval Date.

Termination Date equals the Five and One Half (5.5) Year Anniversary of the Initial Exercise Date

Series X Convertible Preferred Stock has no expiration date

Series X Convertible Preferred Stock has no expiration date.

Series X Convertible Preferred Stock has no expiration date

Shares held by a partnership of which the reporting person is the managing member of the managing partner

Series X Convertible Preferred Stock has no expiration date

Shares held by charitable remainder unitrust of which the reporting person's spouse is the trustee

Shares held by a partnership of which the reporting person is the managing member of the managing partner

Shares held by charitable remainder unitrust of which the reporting person's spouse is the trustee

Options vests 1/3 per year beginning on first anniversary of grant date.

Options vests 1/3 per year beginning on first anniversary of grant date.

Options vests 1/3 per year beginning on the first anniversary of the grant date.

Options vests 20% per year beginning on first anniversary of grant date.

Shares held of record by the M Colombatto Trust, for which the reporting person serves as trustee.

33.33% exercisable on January 29, 2025, 33.33% exercisable on January 29, 2026, and 33.34% exercisable on January 29, 2027.

33.33% exercisable on January 29, 2025, 33.33% exercisable on January 29, 2026, and 33.34% exercisable on January 29, 2027.

90,000 shares exercisable January 29, 2025, 120,000 shares exercisable January 29, 2026, 120,000 shares exercisable January 29, 2027, and 120,000 shares exercisable January 29, 2028.

33.33% exercisable on January 29, 2025, 33.33% exercisable on January 29, 2026, and 33.34% exercisable on January 29, 2027.

20% exercisable on January 29, 2025, 20% exercisable on January 29, 2026, 20% exercisable on January 29, 2027, 20% exercisable on January 29, 2028, and 20% exercisable on January 29, 2029.

Options vest 1/36 every month beginning February 6, 2025

Options vests annually for five years.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.4164 to $0.4319, inclusive on January 22, 2024 and $0.5673 to $0.6304, inclusive on January 23, 2024. The reporting person undertakes to provide Catheter Precision, Inc., any security holder of Catheter Precision, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth above.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.4164 to $0.4319, inclusive on January 22, 2024 and $0.5673 to $0.6304, inclusive on January 23, 2024. The reporting person undertakes to provide Catheter Precision, Inc., any security holder of Catheter Precision, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth above.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $00.3989 to $00.4174, inclusive on January 18, 2024 and $00.4211 to $00.4475, inclusive on January 19, 2024. The reporting person undertakes to provide Catheter Precision, Inc., any security holder of Catheter Precision, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth above.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $00.3989 to $00.4174, inclusive on January 18, 2024 and $00.4211 to $00.4475, inclusive on January 19, 2024. The reporting person undertakes to provide Catheter Precision, Inc., any security holder of Catheter Precision, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth above.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $00.3820 to $00.3923, inclusive on January 16, 2024 and $00.3898 to $00.3968, inclusive on January 17, 2024. The reporting person undertakes to provide Catheter Precision, Inc., any security holder of Catheter Precision, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth above.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $00.3820 to $00.3923, inclusive on January 16, 2024 and $00.3898 to $00.3968, inclusive on January 17, 2024. The reporting person undertakes to provide Catheter Precision, Inc., any security holder of Catheter Precision, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth above.

Options vests 8 1/3% every three months beginning April 8, 2024.

Options vests 20% per year beginning on first anniversary of grant date.

Options vests 8 1/3% every three months beginning on April 8, 2024.

Options vests 8 1/3% every three months beginning on April 8, 2024.

Each share of preferred stock will automatically convert into 1000 shares of common stock on or after July 9, 2024, if the Company satisfies the initial listing standards of a national securities exchange or has been delisted from the NYSE American.

Series X Convertible Preferred Stock has no expiration date.

Shares held by a partnership of which the reporting person is the managing member of the managing partner.

This the transaction was the result of the automatic conversion of shares of Series X Preferred upon receipt of stockholder approval.

This the transaction was the result of the automatic conversion of shares of Series X Preferred upon receipt of stockholder approval.

Series X Convertible Preferred Stock has no expiration date.

Each share of preferred stock will automatically convert into 1000 shares of common stock on or after July 9, 2024, if the Company satisfies the initial listing standards of a national securities exchange or has been delisted from the NYSE American.

Series X Convertible Preferred Stock has no expiration date.

This the transaction was the result of the automatic conversion of shares of Series X Preferred upon receipt of stockholder approval.

Each share of preferred stock will automatically convert into 1000 shares of common stock on or after July 9, 2024, if the Company satisfies the initial listing standards of a national securities exchange or has been delisted from the NYSE American.

Series X Convertible Preferred Stock has no expiration date.

Shares held by charitable remainder unitrust of which the reporting person's spouse is the trustee.

Each share of preferred stock will automatically convert into 1000 shares of common stock on or after July 9, 2024, if the Company satisfies the initial listing standards of a national securities exchange or has been delisted from the NYSE American.

Series X Convertible Preferred Stock has no expiration date.

This transaction was the result of the automatic conversion of shares of Series X Preferred upon receipt of stockholder approval.

This transaction was the result of the automatic conversion of shares of Series X Preferred upon receipt of stockholder approval.

Shares held by a partnership of which the reporting person is the managing member of the managing partner.

This transaction was the result of the automatic conversion of shares of Series X Preferred upon receipt of stockholder approval.

Shares held by charitable remainder unitrust of which the reporting person's spouse is the trustee.